Close

pCDCAR1 GD2 h(γ), T (CAR-T-1-M326-G)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-GD2 chimeric antigen receptor(CAR) is constructed for the engineering of T cells to target Human GD2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-GD2 antibody linked to FcεRIγ signaling domains. And the vector product was designed for the treatment of neuroblastoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • GD2
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Neuroblastoma
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-FcεRIγ
  • Discription of Signaling Cassetes
  • FcεRIγ
    The high-affinity IgE receptor, also known as FcεRI, or Fc epsilon RI, is the high-affinity receptor for the Fc region of immunoglobulin E (IgE). FcεRI is a key molecule involved in allergic reactions. It is a tetramer composed of 1alpha, 1 beta, and 2 gamma chains. The gamma chains are also subunits of other Fc receptors. The scFv-based CARs engineered to contain a signaling domain from FcεRIγ have been shown to deliver a potent signal for T cell activation and function.

Target

  • Clone
  • ch14.18
  • Host
  • Chimeric
  • Target Species
  • Human
  • Gene Name
  • beta-1,4-N-acetyl-galactosaminyltransferase 1
  • Synonyms
  • GD2;B4GALNT1; beta-1,4-N-acetyl-galactosaminyltransferase 1; GALGT; SPG26; GALNACT; GalNAc-T;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FuncS

Fig.1 GD2-CAR T cell killing assay.

CAR Construction : 14.18 scfv-CD28-41BB-CD3ζ Latest CAR Construction

Fig.1 GD2-CAR T cell killing assay.

Target cell killing analysis of the GD2 CAR T cells, 14.18. The OS cells transduced with a lentiviral wasabi green fluorescence reporter gene were used as target cells,
and plated into 96 or 48 wells for 2 hours before adding the different CAR T cells (Jurkat or primary T cells, at E:T ratio 3:1).

Chulanetra, M., Morchang, A., Sayour, E., Eldjerou, L., Milner, R., Lagmay, J., ... & Chang, L. J. (2020). GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas. American journal of cancer research, 10(2), 674.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-GD2 scFv h(FcεRIγ) CART, pCDCAR1 (CAR-T-1-M326-G). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.